EASL Preview: Merck, Gilead, AbbVie, Janssen Make Waves With Abstracts
Executive Summary
Impressive data on Gilead’s combo of sofosbuvir and ledipasvir and information from Merck on when it plans to start a Phase III program for its two-drug hepatitis C combo are among the noteworthy items stemming from a review of abstracts for next month’s European Association for the Study of the Liver conference.